Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,848 total articles
FreightCar America, a leading North American manufacturer of railroad freight cars and related services, announced it will release its Q1 2026 financial results on May 4, 2026, followed by a teleconference on May 5 to discuss the results. The company specializes in the production, repair, and conversion of freight railcars, emphasizing their role i…
First Tracks Biotherapeutics, a clinical-stage biotech company focused on antibody therapies for autoimmune and inflammatory diseases, officially launched as an independent public company on Nasdaq under the ticker TRAX. The company has a strong financial foundation with $180 million in cash and a two-year cash runway. Its pipeline features three d…
GBank Financial Holdings Inc. will release its first quarter 2026 financial results on April 29, 2026, followed by a quarterly earnings call hosted remotely. The company is a Nasdaq-listed bank holding company focused on gaming fintech and SBA lending, with operations spanning four states in the U.S.
Kroll Bond Rating Agency (KBRA) has affirmed Preferred Bank's deposit and debt ratings with a stable outlook, highlighting the bank's robust profitability, high-yield loan portfolio, and efficient branch-light business model. The strong 2025 return on assets (ROA) of 1.84% underpins these ratings. Preferred Bank continues to serve a diverse custome…
PDF Solutions, a Nasdaq-listed company specializing in data solutions for the semiconductor industry, will release its first quarter fiscal 2026 financial results after market close on May 7, 2026. The company's CEO and CFO will host a live teleconference to discuss the results, accessible via webcast and phone.
ServisFirst Bancshares, Inc. announced robust financial results for Q1 2026, highlighting a 31% increase in diluted earnings per share to $1.52 compared to Q1 2025, improved net interest margin of 3.53%, and strong loan and deposit growth. The bank's efficiency ratio improved to under 30%, and key capital ratios strengthened, reflecting sound finan…
Biodesix, Inc., a diagnostic solutions company, will report its first quarter 2026 financial results on May 4, 2026, after market close. The company will hold a conference call to discuss the results and provide a business update. Biodesix offers diagnostic tests for lung disease and supports biopharmaceutical development efforts.
Radware Ltd. announces its 2026 Annual General Meeting (AGM) to be held on May 25, 2026, at its New Jersey office. The agenda includes electing Class III directors, approving equity awards and bonus structure for the CEO, and reappointing the audit firm Kost Forer Gabbay & Kasierer. Financial statements for 2025 will also be presented and discussed…
Parsons Corporation has been selected by the Los Angeles Department of Water & Power (LADWP) to implement its Demand Response Management System (DRMS), significantly boosting LADWP's capacity to integrate distributed energy resources as part of its strategic plan to achieve 100% clean electricity by 2035 or sooner. This contract will enhance grid r…
Ascentage Pharma presented four preclinical studies at AACR 2026 demonstrating the efficacy and synergistic potential of its drug candidates Olverembatinib, APG-2449, and APG-5918 in treating various cancers. These findings support further clinical development and combination therapy strategies for hematologic malignancies and solid tumors, highlig…
ANI Pharmaceuticals announces FDA approval and commercial launch of Pimozide Tablets (1 mg and 2 mg), a generic version of Orap®, with 180-day exclusivity for first generic competition. The product targets a market with approximate annual U.S. sales of $3.1 million, supporting ANI's strategy to deliver limited competition generic products and expan…
Fiserv, Inc., a leading global provider of payments and financial services technology, announced its CEO Mike Lyons will present at major upcoming investor conferences in May, including the J.P. Morgan Global Technology, Media, and Communications Conference and the Bernstein Strategic Decisions Conference. The presentations will be webcast and avai…
Passage Bio announced updated interim data from its Phase 1/2 upliFT-D trial of PBFT02 for frontotemporal dementia with GRN mutations, showing reductions in brain atrophy and stabilization of plasma neurofilament levels in early-stage patients. Despite encouraging biomarker improvements and safety profile, the FDA requires a randomized controlled t…
Capital City Bank Group, Inc. reported first quarter 2026 net income of $15.8 million, $0.92 per diluted share, showing a 15% increase over the prior quarter despite slightly lower net interest income due to fewer calendar days. The bank achieved improved returns on assets and equity, stable credit quality, and strong deposit growth. Noninterest ex…
Lumexa Imaging has appointed Kyle Lynch as its new Chief Growth Officer to lead enterprise growth strategies including joint ventures, acquisitions, and new developments. Lynch will also enhance sales productivity and standardize performance metrics across the company's outpatient imaging centers. This move aims to capitalize on strong sector trend…
Sagimet Biosciences Inc. announced the appointment of Dr. Andreas Grauer as Chief Medical Officer, succeeding Dr. Eduardo Martins who retires and becomes an external scientific advisor. Dr. Grauer brings over 20 years of biopharmaceutical leadership experience and will lead the clinical development of Sagimet's FASN inhibitor drug candidates target…
Axalta Coating Systems has launched Zencore™, a new cabinet coating system designed to streamline manufacturing processes for high-volume operations in North America. Building on the technology of its premium Zenamel™ brand, Zencore™ reduces coating steps from three to two, improving throughput, cost efficiency, and reducing waste without compromis…
Cronos Group Inc. announced it will hold its 2026 first quarter earnings conference call on May 11, 2026, where senior management will discuss financial results and answer investor questions. The company, a global cannabis firm, continues to emphasize its strategy to build a leading international brand portfolio through R&D and innovation.
Sutro Biopharma presented encouraging preclinical data across several antibody-drug conjugate (ADC) programs, including STRO-004, STRO-006, and STRO-227, at the AACR 2026 meeting. STRO-004 demonstrated robust antitumor activity and favorable tolerability in solid tumor models, supporting advancement into clinical trials. Other pipeline candidates s…
Monopar Therapeutics announced Phase 3 trial results of ALXN1840 demonstrating greater neurologic improvement and reduced deterioration in Wilson disease patients with neurologic symptoms, compared to standard of care. The drug showed sustained benefits over multiple years and a favorable safety profile, supporting an FDA NDA submission planned for…
Immunocore Holdings plc announces that KIMMTRAK (tebentafusp-tebn) significantly improves five-year overall survival rates in first-line HLA-A*02:01 positive patients with metastatic uveal melanoma, doubling survival from 8% to 16%. The data, from the longest randomized Phase 3 trial in this disease and for any T cell engager in solid tumors, showc…
Xenon Pharmaceuticals reported highly positive Phase 3 X-TOLE2 study results demonstrating significant seizure frequency reductions with azetukalner in patients with focal onset seizures, alongside promising 48-month long-term efficacy and safety data from the ongoing open-label extension. The data highlights azetukalner's potential as a preferred …
Molecular Partners AG presented new preclinical data supporting its Switch-DARPin T cell engager MP0632 for solid tumors co-expressing MSLN and EpCAM, demonstrating tumor regression with a favorable safety profile. Additionally, the company showcased the molecular characteristics of MP0712, a Radio-DARPin candidate in an ongoing US Phase 1/2a trial…
Revolution Medicines, Inc. presented updated Phase 1 clinical data for zoldonrasib, an oral targeted inhibitor for KRAS G12D non-small cell lung cancer (NSCLC), showing favorable safety and encouraging efficacy results including a 52% objective response rate and prolonged progression-free survival. These results support further clinical development…
Pliant Therapeutics announced updated Phase 1 trial data demonstrating significant antitumor activity of PLN-101095, an oral integrin inhibitor, combined with pembrolizumab in patients with immune checkpoint inhibitor-refractory advanced solid tumors. Confirmed tumor responses showed an average maximum reduction of 89%, with median treatment durati…
